The Market Aktie
WKN DE: A3E16Q / ISIN: AU0000306037
|
26.11.2025 01:17:20
|
Why Novartis Stock Topped the Market Today
Although it's never guaranteed that regulatory approval of a new drug will juice the share price of its developer, this often happens in the pharmaceutical field. Sure enough, after receiving regulatory approval for one of its medications, Novartis (NYSE: NVS) saw a nearly 3% increase in its share price. This easily surpassed the S&P 500 index's gain of 0.9% that trading session. Novartis announced late Monday that the U.S. Food and Drug Administration (FDA) approved its Itvisma for certain forms of spinal muscular atrophy (SMA). The healthcare company didn't hesitate to mention that this makes the drug the first and only gene replacement therapy for the affliction. The approval covered patients two years and older. Image source: Getty Images.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu The Market Limited Registered Shsmehr Nachrichten
Analysen zu Novartis AGmehr Analysen
| 21.11.25 | Novartis Neutral | UBS AG | |
| 21.11.25 | Novartis Buy | Deutsche Bank AG | |
| 21.11.25 | Novartis Underweight | Barclays Capital | |
| 21.11.25 | Novartis Outperform | Bernstein Research | |
| 20.11.25 | Novartis Neutral | UBS AG |
Aktien in diesem Artikel
| Novartis AG ADR Cert. Deposito Arg. Repr. 0.5 ADRs | 46 420,00 | -0,85% |
|
| Novartis AG 2. Linie | 104,68 | 1,28% |
|
| Novartis AG (Spons. ADRS) | 111,50 | 1,83% |
|
| Novartis AG | 112,00 | 2,24% |
|
Letzte Top-Ranking Nachrichten
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.